North Carolina Biotechnology Center

www.ncbiotech.org

The North Carolina Biotechnology Center accelerates life science technology-based economic development through innovation, commercialization, education, and business growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

news image

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More

CELL AND GENE THERAPY

AEGLEA BIOTHERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION AND CORPORATE RESTRUCTURING

Aeglea BioTherapeutics, Inc. | August 25, 2022

news image

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date. The Company also plans to r...

Read More

MEDTECH

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

news image

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

news image

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More
news image

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More
news image

CELL AND GENE THERAPY

AEGLEA BIOTHERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION AND CORPORATE RESTRUCTURING

Aeglea BioTherapeutics, Inc. | August 25, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date. The Company also plans to r...

Read More
news image

MEDTECH

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More